ArticleCardiology research2026
Everolimus-Eluting Stent (Espalier) in Coronary Artery Revascularization: A Retrospective, Investigator-Initiated, Multicenter Study.
Article in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-eluting stents (DESs) are key to percutaneous coronary intervention (PCI), with outcomes shaped by device, patient, and operator factors. The everolimus-eluting stent (EES, Espalier) was assessed in a multicenter, real-world study for safety and efficacy. The study evaluated the clinical outcomes, safety, and procedural success of the indigenous Espalier EES (Cognitive Technologies Pvt. Ltd.) in patients undergoing coronary revascularization at tertiary care centers in India. Methods: This retrospective, multicenter study enrolled 402 adults (≥ 18 years) with native coronary lesions suitable for PCI. The primary endpoint was 12-month target lesion failure (TLF: cardiac death, target vessel myocardial infarction (MI), emergent coronary artery bypass grafting (CABG), or clinically driven target lesion revascularization (TLR)). Secondary endpoints included 6-month TLF, target vessel revascularization (TVR), stent thrombosis, and device/procedural success. Subgroup analyses were performed by age, sex, body mass index (BMI), vessel size, and clinical presentation. Results: At 6 months, adverse events were minimal (0.50%), with no MI or stent thrombosis, one death (0.25%), and one TLF (0.25%). At 12 months, mortality remained 0.25%, with no MI or stent thrombosis, while TVR occurred in 1.49% and TLF in 1.74% of patients. Subgroup analyses revealed higher event rates in older patients (≥ 70 years), those with unstable angina, abnormal electrocardiogram (ECG)/echocardiographic findings, and patients with two comorbidities. Device and procedural success were achieved in all cases (100%), with no failures recorded. Conclusions: The Espalier EES demonstrated high procedural success and low adverse event rates at 12 months, with slightly higher risks observed in elderly and high-risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.